Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 15/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 3/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4020314 | 0.92 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL4025640 | 0.86 | TRPV1 (0.84) | TRPV1NAMPT | |
| SCHEMBL4024918 | 0.82 | TRPV1 (0.65) | TRPV1KDM4EGSK3B | |
| SCHEMBL5657888 | 0.82 | TRPV1 (0.84) | TRPV1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL4020267 | 0.82 | TRPV1 (0.81) | TRPV1 | |
| SCHEMBL5658523 | 0.81 | TRPV1 (0.68) | TRPV1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL4019943 | 0.81 | TRPV1 (0.71) | TRPV1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL5442638 | 0.79 | CLK4 (0.70) | TRPV1 | |
| SCHEMBL5659046 | 0.79 | TRPV1 (0.68) | TRPV1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL5657569 | 0.79 | TRPV1 (0.68) | TRPV1KDM4EMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285563-B2 | Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2007-10-23 | — | — | US | disclosed |
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | ARRB1, OPRL1, CNR1 | TRPV1 37/4885KDM4E 3121/4885MEN1 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.